Healthy Skepticism Library item: 7507

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Stolk P, Willemen MJ, Leufkens HG.
Rare essentials: drugs for rare diseases as essential medicines.
Bull World Health Organ 2006 Sep; 84:(9):745-51

Abstract:

Since 1977, the WHO Model List of Essential Medicines (EML), published by WHO, has provided advice for Member States that struggle to decide which pharmaceutical technologies should be provided to patients within their public health systems. Originating from outside WHO, an incentive system has been put in place by various governments for the development of medicines for rare diseases (“orphan drugs”). With progress in pharmaceutical research (e.g. drugs targeted for narrower indications), these medicines will feature more often on future public health agendas. However, when current definitions for selecting essential medicines are applied strictly, orphan drugs cannot be part of the WHO Essential Medicines Programme, creating the risk that WHO may lose touch with this field. In our opinion WHO should explicitly include orphan drugs in its policy sphere by composing a complementary Orphan Medicines Model List as an addition to the EML. This complementary list of “rare essentials” could aid policy-makers and patients in, for example, emerging countries to improve access to these drugs and stimulate relevant policies. Furthermore, inconsistencies in the current EML with regard to medicines for rare diseases can be resolved. In this paper we propose selection criteria for an Orphan Medicines Model List that could form a departure point for future work towards an extensive WHO Orphan Medicines Programme.

Keywords:
Cost-Benefit Analysis Decision Making, Organizational Drugs, Essential*/economics Drugs, Essential*/supply & distribution Health Priorities* Health Services Accessibility/economics Humans Needs Assessment Organizational Policy Orphan Drug Production* Policy Making Public Health Administration* Rare Diseases/drug therapy* Rare Diseases/economics Resource Allocation Risk Assessment Social Justice World Health Organization*